Precigen reports third quarter 2024 financial results and business updates

–   completed pre-bla meeting with fda with full alignment on content of bla, including cmc module, and path for fourth quarter 2024 rolling bla submission for prgn-2012 †  in rrp under accelerated approval pathway – –   commercial and manufacturing readiness campaign underway for prgn-2012 in anticipation of a potential 2025 launch – –   confirmatory clinical trial for prgn-2012 in rrp was initiated in accordance with guidance from fda to initiate prior to submission of the bla; continuing enrollment – –   preparing for end of phase 1b meeting with fda in early 2025 for prgn-3006 in aml – –   presented preclinical data at sitc 2024 for prgn-3008, a next generation ultracar-t targeting cd19 showcasing potential to be best-in-class cd19-targeting car-t treatment in oncology and autoimmunity – germantown, md. , nov. 14, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2024 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking